CA2358967A1 - Proformes d'hesperitine ayant une disponibilite biologique accrue - Google Patents

Proformes d'hesperitine ayant une disponibilite biologique accrue Download PDF

Info

Publication number
CA2358967A1
CA2358967A1 CA002358967A CA2358967A CA2358967A1 CA 2358967 A1 CA2358967 A1 CA 2358967A1 CA 002358967 A CA002358967 A CA 002358967A CA 2358967 A CA2358967 A CA 2358967A CA 2358967 A1 CA2358967 A1 CA 2358967A1
Authority
CA
Canada
Prior art keywords
acid salt
pro
moiety
hesperetin
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002358967A
Other languages
English (en)
Inventor
Jan E. Zielinski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ZIELINSKI LABORATORY
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2358967A1 publication Critical patent/CA2358967A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/28—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 2 only
    • C07D311/32—2,3-Dihydro derivatives, e.g. flavanones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrane Compounds (AREA)

Abstract

Cette invention concerne une proforme d'hespéritine, ainsi qu'une proforme d'hespérétine hydrophile et lipophile. Cette invention concerne également une composition pharmaceutique qui peut être administrée à un individu par voie orale ou topique, et qui comprend une proforme d'hespérétine hydrophile ainsi qu'un excipient acceptable sur le plan pharmaceutique. Cette invention aussi une composition pharmaceutique qui peut être administrée à un individu par voie orale ou topique, et qui comprend une proforme d'hespérétine lipophile ainsi qu'un excipient acceptable sur le plan pharmaceutique. Cette invention concerne également un procédé permettant de traiter un sujet qui souffre ou risque de souffrir de troubles de prolifération cellulaire, et qui consiste à administrer audit sujet une quantité efficace sur le plan thérapeutique d'une proforme d'hespérétine.
CA002358967A 1999-01-27 2000-01-26 Proformes d'hesperitine ayant une disponibilite biologique accrue Abandoned CA2358967A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US11756799P 1999-01-27 1999-01-27
US11819899P 1999-02-01 1999-02-01
US60/117,567 1999-02-01
US60/118,198 1999-02-01
PCT/US2000/001923 WO2000044757A1 (fr) 1999-01-27 2000-01-26 Proformes d'hesperitine ayant une disponibilite biologique accrue

Publications (1)

Publication Number Publication Date
CA2358967A1 true CA2358967A1 (fr) 2000-08-03

Family

ID=26815410

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002358967A Abandoned CA2358967A1 (fr) 1999-01-27 2000-01-26 Proformes d'hesperitine ayant une disponibilite biologique accrue

Country Status (6)

Country Link
EP (1) EP1155021A1 (fr)
JP (1) JP2002535410A (fr)
CN (1) CN1337966A (fr)
AU (1) AU764186B2 (fr)
CA (1) CA2358967A1 (fr)
WO (1) WO2000044757A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4522624B2 (ja) * 2001-09-27 2010-08-11 株式会社ポッカコーポレーション レモン発酵物及びその製造方法
JP4522625B2 (ja) * 2001-09-27 2010-08-11 株式会社ポッカコーポレーション 柑橘属発酵物及びその製造方法
NZ560633A (en) * 2005-03-11 2011-08-26 Neuprotect Pty Ltd Flavonoid compounds and uses thereof
MX2010001141A (es) 2007-07-31 2010-03-01 Limerick Biopharma Inc Analogos fosforiladosde pirona y metodos.
CN102746264A (zh) * 2012-08-06 2012-10-24 西南大学 7-苯甲氧基橙皮素及其制备方法和用途
CN106565657A (zh) * 2016-11-23 2017-04-19 陕西科技大学 一种具抗肿瘤活性的橙皮素肉桂酸酯类化合物及其合成方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0695181A1 (fr) * 1993-04-20 1996-02-07 The Procter & Gamble Company Procedes d'utilisation d'hesperetine pour la reduction du sebum et pour le traitement de l'acne
KR100213895B1 (ko) * 1996-10-14 1999-08-02 박원훈 감귤류 과피 추출물, 이로부터 분리 정제된 헤스페리딘 또는 나린진을 포함하는 심혈관 질환 예방및 치료제 조성물

Also Published As

Publication number Publication date
CN1337966A (zh) 2002-02-27
EP1155021A1 (fr) 2001-11-21
WO2000044757A1 (fr) 2000-08-03
AU2630900A (en) 2000-08-18
JP2002535410A (ja) 2002-10-22
AU764186B2 (en) 2003-08-14

Similar Documents

Publication Publication Date Title
CN108864024A (zh) 一类灯盏乙素苷元氮芥类衍生物及其制备方法和用途
US6699900B2 (en) Hydrophilic and lipophilic silibinin pro-forms
CN1188482A (zh) 秋水仙碱衍生物,其应用及含它们的制剂
AU764186B2 (en) Hesperitin pro-forms with enhanced bioavailability
CN101863934A (zh) 水杨酸甲酯糖苷类化合物、其合成方法与用途
CN113336765A (zh) 一种莪术醇酯化物、制备方法及其在治疗结直肠癌药物中的应用
CN104151379A (zh) 一种Kinsenoside及GoodyerosideA类似物的制备与用途
US6831098B1 (en) Hesperetin pro-forms with enhanced bioavailablility
CN103242337B (zh) 一种基于paf/ros双靶点的银杏内酯b衍生物及其制备方法
CN101974016A (zh) 酰胺类化合物及其制备方法和用途
CZ280027B6 (cs) Arylalkylestery 4,5-dihydroxy-9,10-dihyhro-9,10-dioxo-2-anthracenkarboxylových kyselin, způsob výroby a farmaceutické prostředky s jejich obsahem
CN102260239B (zh) 胡黄连素衍生物及其制备与应用
US20230055908A1 (en) Mesylate salt of para-topolin, compositions containing said salt and use thereof
AU2006319748B2 (en) Biologically active compounds
FI112658B (fi) Menetelmä uusien kardioprotektiivisten hydroksibentsopyraani-2-karboksyylihappojohdannaisten ja niiden laktonien valmistamiseksi
US20070105946A1 (en) Tocopherol derivatives with a long hydroxylated chain, which can be used as neurotrophics
US7528166B2 (en) Lignan derivatives
CN115385875B (zh) 一类紫杉醇衍生物及其制备方法和用途
CN101497590A (zh) 13-烷氧代-3,15-二氧代赤霉酸酯及其制备方法
Wijeratne et al. Synthesis and preliminary biological evaluation of β-carotene and retinoic acid oxidation products
PL237703B1 (pl) 6-Metoksy-3’-O-β-D-(4’’-O-metyloglukopiranozylo)-flawon i sposób wytwarzania 6-metoksy-3’-O-β-D-(4’’-O-metyloglukopiranozylo)- flawonu
WO2023099549A1 (fr) Procédé de synthèse et de purification d'acides cannabinoïdes et de dérivés acylés de ceux-ci
PL237701B1 (pl) 2’-Metoksy-5’-O-β-D-(4”-O-metyloglukopiranozylo)-flawanon i sposób wytwarzania 2’-metoksy-5’-O-β-D-(4”-O-metyloglukopiranozylo)- flawanonu
EP4249479A1 (fr) Dérivé de glucoside, son procédé de préparation et son application
CN116514744A (zh) 糖靶向的gsh响应紫杉醇衍生物及其制备方法和应用

Legal Events

Date Code Title Description
FZDE Dead